Bavarian Nordic

Our Chikungunya vaccine has officially arrived in the United States and is now commercially available! This marks a pivotal moment in our mission to combat chikungunya and help protect countless individuals from its impact. At Bavarian Nordic, our dedicated team has put in immense effort to develop and deliver this vaccine, and we are proud to contribute to the fight against this disease. Discover more insights here: https://lnkd.in/dDRCY35h Join us in the fight against chikungunya.   #ProtectingAndSavingLives #Chikungunya #Vaccine

Earlier this week, we had the pleasure of welcoming a delegation from the European Commission Health Emergency Preparedness and Response Authority (HERA) to our headquarters in Copenhagen. Among the delegation was Laurent Muschel, Head of the EU Commission Health Emergency Preparedness and Response Authority (HERA). Their visit highlighted the crucial role our public-private partnership plays in ensuring access to essential medical countermeasures, especially amidst the ongoing mpox Public Health Emergency of International Concern (PHEIC) and our shared efforts to control outbreaks in Africa. We look forward to continuing this vital collaboration and exploring new ways to enhance our efforts on medical countermeasures for mpox and smallpox. Together, we are protecting and saving lives. #BavarianNordic #ProtectingAndSavingLives #mpox #HERA

#IWD2025 On International Women’s Day, we want to highlight the actions our colleagues take to create an inclusive workplace. This year, we kicked off with a fantastic event with HBA EMEA at our Munich office focusing on women innovators. All actions at Bavarian Nordic are guided by our DNA #Boostedbytheteam and commitment to nurture an inclusive workplace where everyone feels safe, respected, and valued, regardless of background, identity, or beliefs. Meet some of our colleagues as they share their actions for inclusivity. What actions do you take? 👇 Let’s #AccelerateAction

Yet another milestone in our chikungunya journey is achieved. We are thrilled to share the acceptance of our submitted marketing authorization application by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for our chikungunya vaccine for persons aged 12 and older. The submission to MHRA was enabled by the recent positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), potentially supporting approval in the UK in the first half of 2025. With our recent organizational expansion into the UK, we are strongly positioned to leverage the strengths of our growing travel health portfolio to support the launch of our chikungunya vaccine. Read the full press release here: https://lnkd.in/db6myJCy #Chikungunya #TravelHealth #BavarianNordic #MHRA

2024 has been an extraordinary year of achievements. Yesterday, we published our 2024 annual report. Our CEO, Paul Chaplin, highlights our success in surpassing financial targets, swiftly responding to the mpox outbreak in the Democratic Republic of Congo, and expanding access to our life-saving vaccines. Together, we're not just tackling today's challenges but also paving the way for a healthier tomorrow. Dive into our 2024 annual report here: https://lnkd.in/dCzdDdgG #BavarianNordic #AnnualReport #ProtectingOurTomorrow

Our full-year results for 2024 are out! This past year has been one of unwavering dedication and remarkable achievements. 2024 marks our fifth consecutive year of growth and progress. As we step into 2025, we're eager to build on this strong foundation and continue pioneering vaccine innovation. With regulatory approvals secured in both the US and Europe, we're gearing up to launch our Chikungunya vaccine in key markets during the first half of the year. Today, we also announced two new pipeline candidates: one targeting Lyme disease and another targeting the Epstein-Barr Virus (EBV). These groundbreaking candidates are set to enter phase 1 trials in 2026, driving future growth and addressing critical medical needs. Dive into our 2024 annual report here: https://lnkd.in/dCzdDdgG #BavarianNordic #BavarianNordicAnnualReport2024 #AnnualReport #ProtectingAndSavingLives

We are thrilled to announce that our chikungunya vaccine has been granted marketing authorization in Europe by the European Commission, marking a significant step in the fight against this disease. With this approval, we can now provide effective protection against chikungunya across Europe, ensuring unmet travel health for individuals as young as 12 years. The marketing authorization was granted by the European Commission upon recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in January 2025 and was based on results from two phase 3 clinical trials. This approval is a testament to our team's tireless efforts and commitment to protecting lives everyday. Read the press release here: https://lnkd.in/dN3YNvHR #BavarianNordic #Chikungunya #EMAApproval

Every day, our teams are driven by a shared mission: preventing diseases through education and innovation. One of our key focus areas is Tick-Borne Encephalitis (TBE), a serious viral infection that can lead to severe neurological complications. TBE cases are on the rise due to climate change, increased outdoor activities, and improved diagnostics. This is why we are committed to raising awareness and providing innovative solutions to help protect people worldwide. Together, we can make a difference. Join us in spreading knowledge and promoting preventive measures to safeguard individuals and communities against TBE. #WorldEncephalitisDay #TickBorneEncephalitis #Red4WED #WEDAppeal

We are committed to ensuring timely access to our innovative vaccines for all communities. Being fully prepared is essential in expanding access to our vaccines. That’s why we are pleased to announce a contract manufacturing agreement with Biological E. Limited (BE), on the future manufacturing of our chikungunya vaccine outside western markets. A proactive partnership purposed to expand access in low- and middle-income (LMIC) countries. “We are pleased to announce our first collaboration to expand global access to our chikungunya vaccine and also our first partnership with Biological E, who have solid expertise and comprehensive experience in supplying vaccines for improving public health worldwide,” said Paul Chaplin, President & CEO of Bavarian Nordic. “Expanding supply is a prerequisite for our ability to address the increasing need for solutions to prevent chikungunya in vulnerable populations in endemic regions, and we are dedicated to pursuing strong partnerships that can help us achieve this goal.” For more details, please see our latest press release here: https://lnkd.in/dp-q-vex #BavarianNordic #ProtectingOurTomorrow #CMO #Chikungunya

Raising awareness is key to improving understanding and protecting individuals from Tick-Borne Encephalitis. Today is #WorldEncephalitisDay, and we are proud to once again sponsor this important cause and raise awareness alongside our partner, Encephalitis International. Did you know these five key facts about encephalitis? Swipe through the carousel below to learn more about encephalitis or visit: https://lnkd.in/dPJRrvJi. #WorldEncephalitisDay #TickBorneEncephalitis #Red4WED #WEDAppeal